From its initial founding in 1946 as a brick-and-mortar bookstore in Houston, Texas, ProBility Media Corp. (OTCQB: PBYA) has taken off, migrating its services online to the cloud. As a result, its revenues have moved up, too. The company’s latest filing reports that net sales for the quarter ended January 31, 2017, rose year-over-year by 24 percent. Now the EdTEch company, aiming to become one of the largest providers of skilled trades education and training in the United States, has begun to explore international expansion to the countries that have adopted U.S.-based codes and training. ProBility Media Corp. continues its strategy to build the first full service training and career advancement brand for the skilled trades.
The company’s latest quarterly (10-Q) filing, for the quarter to January 31, 2017, shows management has been aggressive. Apart from achieving record quarterly sales that crossed the million-dollar mark for the first time, they have been actively engaging in the art of the deal by completing two acquisitions, including the acquisition of One Exam Prep LLC, which offers low-cost yet effective exam prep courses in the construction industry. One Exam Prep, based in Coconut Creek, Florida, owns more than 70 domains related to contractor licensing and continuing education and has created hundreds of courses offered either online or in traditional classroom settings in more than 20 states.
ProBility also signed off on its acquisition of Premier Purchasing and Marketing Alliance LLC. Premier, doing business as National Electrical Wholesale Providers (NEWP), services electrical wholesalers throughout the United States with study materials for electricians, including the National Electrical Code. The company provides a complete line of printed reference materials in addition to e-books, downloadable digital formatting and mobile applications to all distributors. NEWP also provides HVAC, plumbing, industrial and residential trade reference materials with online training for product education, certification and current code practices.
NEWP has significant corporate accounts with electrical wholesale conglomerates, making it one of the largest wholesalers of National Electrical Codes in the United States. It services several multibillion-dollar companies such as Consolidated Electrical Distributors and Home Depot, reaching thousands of accounts in locations throughout the United States.
ProBility also signed an exclusive publishing and distribution deal with All Purpose Crane Training (AP), which provides nationwide crane-rigging training and certification that meets OSHA-ANSI requirements. OSHA is the Occupational Safety and Health Administration; ANSI is the American National Standards Institute.
The courses, customized to meet the specific needs of customers, can be taken either at the customer’s site or at AP’s training centers around the country. They include aerial lift operator training, forklift operator certification, crane rigging instructor courses, mobile crane operator certification, crane operator training, overhead crane training, and rigging and signal-person qualification training.
In addition to these major deals, ProBility has entered into two new publishing contracts. The first is with Ralph Dewey, author of the most widely-distributed instrumentation texts in the industry. Titles include The Purdy’s Instrument Handbook, The Purdy’s Instrument Handbook #2, and Dewey’s Troubleshooting Handbook, all of them staples for professionals who operate in instrumentation or related fields. ProBility will also be the exclusive distributor and publisher of the new release of The Purdy’s Instrument Pocket Guide, to be released soon. This guide will include all the highlights from the three handbooks in a pocket-sized edition.
The company’s second contract is with Pat Ginther for his bestselling book, The Sheet Metal Pocket Guide, created for engineers who design in sheet metal and who are looking for the latest techniques and best practices.
ProBility has signaled its rise to the top with an uplisting to the QB Tier of the OTC Markets. To qualify for the listing, a company must demonstrate that it is current in its reporting requirements to the Securities and Exchange Commission and commits to undergo an annual management certification process to verify officers, directors, controlling shareholders and shares outstanding.
ProBility Media Corp. may have taken off, but it hasn’t left transparency behind.
For more information, visit the company’s website at www.ProBilityMedia.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, April 11, 2017
One Step Vending Corp. (KOSK) is “One to Watch”
One Step Vending Corp. (OTC: KOSK) is focused on growing through acquisitions and cooperative agreements with companies that have potential and capabilities of achieving sustainable growth and rapidly capturing market share. The company provides financing and operational business support while also helping build key growth strategies. Key business sectors actively targeted include food and refreshment services, self-checkout systems and mobile vending machines.
Corporate Refreshment Services (CRS) Micro Markets Inc., a subsidiary of One Step Vending, is a self-checkout retailer that offers a wide range of food and beverages. Regardless if a traditional vending machine or the high-tech micro market is chosen, the location’s patrons enjoy gourmet market deliciousness and quick market convenience.
Mainly targeting the office environment, the micro markets offer a fresh market-grab and go-food concept that doesn’t cost the business anything to host. Each micro market can be customized for any size or look and feature an easy-to-use touch screen interface so anyone can easily shop, scan and pay for their items. Once installed, employees benefit from a diverse menu that includes healthy snacks, real food, classic vending favorites and much more.
The team behind this concept has been committed to staying at the forefront of vending technology for 15 years. By replacing traditional vending machines with micro markets, they experienced up to five times greater revenue in large accounts. Today, the groundwork is laid with unique capabilities and proven execution strategies.
With CRS Micro Markets Inc. setting the example, One Step Vending’s mission is to support thousands of businesses in the realization of their business goals by delivering experiences that enrich and nourish. Fostering a winning network of associates and partners and building mutually loyalty and trust is core to the company’s growth strategy.
For more information, visit the company’s website at www.OneStepVending.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Corporate Refreshment Services (CRS) Micro Markets Inc., a subsidiary of One Step Vending, is a self-checkout retailer that offers a wide range of food and beverages. Regardless if a traditional vending machine or the high-tech micro market is chosen, the location’s patrons enjoy gourmet market deliciousness and quick market convenience.
Mainly targeting the office environment, the micro markets offer a fresh market-grab and go-food concept that doesn’t cost the business anything to host. Each micro market can be customized for any size or look and feature an easy-to-use touch screen interface so anyone can easily shop, scan and pay for their items. Once installed, employees benefit from a diverse menu that includes healthy snacks, real food, classic vending favorites and much more.
The team behind this concept has been committed to staying at the forefront of vending technology for 15 years. By replacing traditional vending machines with micro markets, they experienced up to five times greater revenue in large accounts. Today, the groundwork is laid with unique capabilities and proven execution strategies.
With CRS Micro Markets Inc. setting the example, One Step Vending’s mission is to support thousands of businesses in the realization of their business goals by delivering experiences that enrich and nourish. Fostering a winning network of associates and partners and building mutually loyalty and trust is core to the company’s growth strategy.
For more information, visit the company’s website at www.OneStepVending.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
eXp World Holdings, Inc. (EXPI) Using the Internet to Complement Real Estate Agents, Not Replace Them
Most businesses across numerous industries would agree that the internet has disrupted them in one way or another, either positively or negatively. Some believe the internet has led to technological advancements never seen before that have enabled them to cut costs, keep their information safe, and make certain day-to-day tasks easier. Others have seen the internet lead to an increase in unemployment, more space for security breaches, and a lack of human touch when it comes to interactions with consumers.
But how has the proliferation of the internet disrupted those in the real estate industry? Recent studies (http://dtn.fm/0wF0F) show that real estate agents in the U.S. are still receiving their usual 5% to 6% commission on home sales, and, despite the internet having had a negative impact on many of the middlemen from various industries, the commission that real estate agents receive has increased since the early 2000s. Although many assumed real estate agents would struggle because of the internet, the number of agents has actually grown by more than 50% in the past 20 years.
What many have not realized is that the internet has affected the industry as a whole, but has not affected the ever-growing need for agents. The internet has changed the way agents work and interact with their clients for the better, because, although consumers are doing more of the home buying research online, they still have a big decision to make, and therefore turn to agents and brokers for help. More has also been done by real estate companies in terms of advertising to keep the focus on their agents, for example, Century 21’s “Good Luck, Robots” TV commercial (http://dtn.fm/aDtl9).
eXp World Holdings, Inc. (OTCQB: EXPI) is showing the importance of real estate agents and brokers through a different approach, by embracing technology and using it to leverage the ability of agents. The rapidly growing company (its agent roster is expected to double in this year alone) has been referred to as the “Amazon” of real estate. It’s an agent-owned brokerage that has cut out the need for brick and mortar facilities with the use of the cloud, but without cutting out the much-needed agents that run it. Instead of using the internet to replace its brokers and agents, EXPI is using it as a tool to maximize agent-ownership, and agents love it.
EXPI is the first company to ever use 3D, fully immersive cloud-based tools and techniques that allow agents to meet colleagues, share advice, learn through virtual classes, and build strategies to further grow their businesses. EXPI has created this business model not to cut out the middleman, but to show Americans that relying less on traditional offices and adopting technological advancements offer significant benefits to both business growth and customer satisfaction.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
But how has the proliferation of the internet disrupted those in the real estate industry? Recent studies (http://dtn.fm/0wF0F) show that real estate agents in the U.S. are still receiving their usual 5% to 6% commission on home sales, and, despite the internet having had a negative impact on many of the middlemen from various industries, the commission that real estate agents receive has increased since the early 2000s. Although many assumed real estate agents would struggle because of the internet, the number of agents has actually grown by more than 50% in the past 20 years.
What many have not realized is that the internet has affected the industry as a whole, but has not affected the ever-growing need for agents. The internet has changed the way agents work and interact with their clients for the better, because, although consumers are doing more of the home buying research online, they still have a big decision to make, and therefore turn to agents and brokers for help. More has also been done by real estate companies in terms of advertising to keep the focus on their agents, for example, Century 21’s “Good Luck, Robots” TV commercial (http://dtn.fm/aDtl9).
eXp World Holdings, Inc. (OTCQB: EXPI) is showing the importance of real estate agents and brokers through a different approach, by embracing technology and using it to leverage the ability of agents. The rapidly growing company (its agent roster is expected to double in this year alone) has been referred to as the “Amazon” of real estate. It’s an agent-owned brokerage that has cut out the need for brick and mortar facilities with the use of the cloud, but without cutting out the much-needed agents that run it. Instead of using the internet to replace its brokers and agents, EXPI is using it as a tool to maximize agent-ownership, and agents love it.
EXPI is the first company to ever use 3D, fully immersive cloud-based tools and techniques that allow agents to meet colleagues, share advice, learn through virtual classes, and build strategies to further grow their businesses. EXPI has created this business model not to cut out the middleman, but to show Americans that relying less on traditional offices and adopting technological advancements offer significant benefits to both business growth and customer satisfaction.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Value Drivers of InMed Pharmaceuticals Inc. (IMLFF)
The cannabis plant is comprised of, among other things, phytochemicals that have evolved over time to become very biologically active. Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids. To date, over 90 cannabinoids have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for distinctive pharmacological effects. The cannabinoids that bind more selectively to certain receptors have become more desirable for medical usage because of the advantage offered. Examples of phytochemicals that have been developed into pharmaceutical drugs include the bronchodilator (asthma), salicin (aspirin) and a number of cardiovascular agents.
InMed Pharmaceuticals is a Canadian drug discovery and development company with a unique focus on this area of cannabinoid science and the curative capabilities of cannabinoids. Since the 1980s, InMed has been developing a robust pipeline of therapies and products by leveraging its primary value drivers: its leadership team and its research and development into the extensive pharmacology of cannabinoids; its proprietary drug discovery platform; its proprietary cannabinoid manufacturing system; and its inventive drug delivery systems.
InMed benefits from the leadership of tested experts like Dr. Ado Muhammed, the company’s Chief Medical Officer. A proven leader in the field of cannabinoid therapies, Muhammed previously served as Associate Medical Director at GW Pharmaceuticals, a $3 billion cannabis biotechnology company. There, he played a strategic role in the delivery of core clinical research and key decision-making regarding R&D and product commercialization. Moreover, he was instrumental in leading that company through the development and regulatory approval of one of the first cannabis drugs in existence. InMed prides itself on being the only cannabis biotech company with a former GW Pharmaceuticals executive on board. This is a significant occurrence, as GW Pharmaceuticals is viewed as “the cannabis industry leader,” as well as a long-term biotech investment with a promising future. Since 2013, GW Pharmaceuticals’ shares have shot up from less than $9 to over $121 as of March 30, 2017, bringing it to a market value of approximately $2.9 billion.
Bioinformatics assessment is another of InMed’s core value drivers. As a general approach, this type of assessment opens up the world for future drug discovery, as it combines scores of data sets and builds holistic models to approach a specific disease. As part of its operations, InMed has created a computer-based program that assists in the discovery of novel cannabinoids using: (a) far-reaching algorithms to integrate data from various bioinformatics databases, (b) a database on the structure of currently-approved pharmaceutical products, and (c) a broad database containing the 90-plus individual cannabinoid drugs that have been found in cannabis. The company is now using this bioinformatics assessment tool to classify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases and to, ultimately, identify new drug candidates that heighten the therapeutic benefits of cannabis while restricting its adverse effects.
Biosynthesis — a process used in industrial applications, including the use of bacteria- or yeast-based systems for the production of pharmaceuticals — is also one of InMed’s primary value drivers. InMed is currently building up a high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This process integrates the inbuilt safety and known effectiveness of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s proprietary approach to the production of pharmaceutical grade, bio-identical cannabinoids is a disruptive technology in the current and rapidly-emerging cannabinoid pharmaceutical sector.
Along with its proprietary in silico drug/disease bioinformatics assessment tool and its cannabinoid biosynthesis technology, InMed’s drug development pipeline is also a core asset. The company is leveraging a conservative clinical budget and accelerated drug development timelines to target unmet medical conditions using its disease-specific formulations. Presently, the company has two drug candidates in its pipeline:
-- INM-750 is under pre-clinical development for the treatment of epidermolysis bullosa, an orphan pediatric disease that is typified by extremely fragile skin. Epidermolysis bullosa has no current approved therapies and represents an estimated $1 billion market.
-- INM-085 is under pre-clinical development for the treatment of glaucoma, a severe eye disease with a global market of approximately $5.6 billion.
InMed Pharmaceuticals is also seeking and developing novel drug candidates for the treatment of conditions relating to dermatology, pain and inflammation, metabolic and respiratory diseases, and the ocular region and central nervous system.
For more information, visit the company’s website at www.InMedPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
InMed Pharmaceuticals is a Canadian drug discovery and development company with a unique focus on this area of cannabinoid science and the curative capabilities of cannabinoids. Since the 1980s, InMed has been developing a robust pipeline of therapies and products by leveraging its primary value drivers: its leadership team and its research and development into the extensive pharmacology of cannabinoids; its proprietary drug discovery platform; its proprietary cannabinoid manufacturing system; and its inventive drug delivery systems.
InMed benefits from the leadership of tested experts like Dr. Ado Muhammed, the company’s Chief Medical Officer. A proven leader in the field of cannabinoid therapies, Muhammed previously served as Associate Medical Director at GW Pharmaceuticals, a $3 billion cannabis biotechnology company. There, he played a strategic role in the delivery of core clinical research and key decision-making regarding R&D and product commercialization. Moreover, he was instrumental in leading that company through the development and regulatory approval of one of the first cannabis drugs in existence. InMed prides itself on being the only cannabis biotech company with a former GW Pharmaceuticals executive on board. This is a significant occurrence, as GW Pharmaceuticals is viewed as “the cannabis industry leader,” as well as a long-term biotech investment with a promising future. Since 2013, GW Pharmaceuticals’ shares have shot up from less than $9 to over $121 as of March 30, 2017, bringing it to a market value of approximately $2.9 billion.
Bioinformatics assessment is another of InMed’s core value drivers. As a general approach, this type of assessment opens up the world for future drug discovery, as it combines scores of data sets and builds holistic models to approach a specific disease. As part of its operations, InMed has created a computer-based program that assists in the discovery of novel cannabinoids using: (a) far-reaching algorithms to integrate data from various bioinformatics databases, (b) a database on the structure of currently-approved pharmaceutical products, and (c) a broad database containing the 90-plus individual cannabinoid drugs that have been found in cannabis. The company is now using this bioinformatics assessment tool to classify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases and to, ultimately, identify new drug candidates that heighten the therapeutic benefits of cannabis while restricting its adverse effects.
Biosynthesis — a process used in industrial applications, including the use of bacteria- or yeast-based systems for the production of pharmaceuticals — is also one of InMed’s primary value drivers. InMed is currently building up a high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This process integrates the inbuilt safety and known effectiveness of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s proprietary approach to the production of pharmaceutical grade, bio-identical cannabinoids is a disruptive technology in the current and rapidly-emerging cannabinoid pharmaceutical sector.
Along with its proprietary in silico drug/disease bioinformatics assessment tool and its cannabinoid biosynthesis technology, InMed’s drug development pipeline is also a core asset. The company is leveraging a conservative clinical budget and accelerated drug development timelines to target unmet medical conditions using its disease-specific formulations. Presently, the company has two drug candidates in its pipeline:
-- INM-750 is under pre-clinical development for the treatment of epidermolysis bullosa, an orphan pediatric disease that is typified by extremely fragile skin. Epidermolysis bullosa has no current approved therapies and represents an estimated $1 billion market.
-- INM-085 is under pre-clinical development for the treatment of glaucoma, a severe eye disease with a global market of approximately $5.6 billion.
InMed Pharmaceuticals is also seeking and developing novel drug candidates for the treatment of conditions relating to dermatology, pain and inflammation, metabolic and respiratory diseases, and the ocular region and central nervous system.
For more information, visit the company’s website at www.InMedPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Grey Cloak Tech, Inc. (GRCK) is “One to Watch”
Grey Cloak Tech, Inc. (OTC: GRCK) is a developer of industry-leading click-fraud detection software designed to overcome the most expensive and devastating threats in the digital world. Through its recently acquired subsidiary, ShareRails, Grey Cloak now also provides sophisticated e-commerce tools that help retailers evolve beyond their brick-and-mortar business practices to increase both their digital engagement and their foot traffic.
ShareRails is an online-to-offline technology firm that provides vitally important services within the trillion-dollar retail sector, helping brick-and-mortar retailers compete directly for online awareness with e-commerce-only brands. Through the ShareRails O2O platform, offline retailers can use online channels to more effectively drive sales and attract new customers.
The innovative solutions offered by ShareRails enable local retailers to capture the millions of online shopping searches they are currently missing out on because their product inventories and other key information is not currently available online and, therefore, does not appear in relevant searches and cannot be viewed digitally.
Most of today’s retail sales are Web-influenced. By utilizing digital marketing channels, merchants can enhance the in-store shopping experience for customers and simultaneously boost sales. The ShareRails O2O platform enables retailers to put their product catalogs online, along with product location and availability, and make the information searchable. The platform also offers digital merchandising tools that include an outfit builder and wishlist app along with conversational shopping tools. Through ShareRails O2O, merchants can additionally tap into data that details shopper insights and behavioral trends. Add-on services include click-n-collect, reservations for in-store pickup, and local delivery.
ShareRails additionally offers Dress.li, which is a recommendation and reward platform that connects shoppers to stylists, bloggers and other fashion influencers who provide them with expert shopping advice and uniquely styled looks and, simultaneously, connects the consumers to fashion retailers. Through Dress.li, the challenge of creating a seamless social shopping experience has finally been mastered! This platform facilitates live shopping communications, curation and content creation and lets users join a global network of trendsetters. Through this network, users can inspire and be inspired, accessing and sharing product recommendations and unique looks and receiving rewards each time another user makes a purchase from their recommendations. This platform not only provides an enjoyable and exciting network for shoppers and fashionistas, but it simultaneously supplies retailers with a lucrative outlet for acquiring new customers through a built-in global sales force of fashion influencers. As these Dress.li stylists create and share looks, they also deliver pre-qualified sales leads and conversions and are rewarded for doing so.
Joined together, Grey Cloak Tech’s industry-leading click-fraud detection solutions and the exciting retail-boosting products delivered through ShareRails offer a broad package of services to both protect businesses in the digital world and help them utilize digital channels to bolster their sales and enhance customer engagement.
Grey Cloak Tech continues to serve as an industry leader in developing the most effective and comprehensive weapons to fight online security threats. The company is keenly focused on protecting its clients’ interests through the identification of fraud patterns at the very earliest stages. When businesses partner with Grey Cloak Tech, they can look forward to benefiting from industry-leading technology, a top-tier client services team, and an augmented bottom line.
For more information, visit the company’s website at www.GreyCloakTech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
ShareRails is an online-to-offline technology firm that provides vitally important services within the trillion-dollar retail sector, helping brick-and-mortar retailers compete directly for online awareness with e-commerce-only brands. Through the ShareRails O2O platform, offline retailers can use online channels to more effectively drive sales and attract new customers.
The innovative solutions offered by ShareRails enable local retailers to capture the millions of online shopping searches they are currently missing out on because their product inventories and other key information is not currently available online and, therefore, does not appear in relevant searches and cannot be viewed digitally.
Most of today’s retail sales are Web-influenced. By utilizing digital marketing channels, merchants can enhance the in-store shopping experience for customers and simultaneously boost sales. The ShareRails O2O platform enables retailers to put their product catalogs online, along with product location and availability, and make the information searchable. The platform also offers digital merchandising tools that include an outfit builder and wishlist app along with conversational shopping tools. Through ShareRails O2O, merchants can additionally tap into data that details shopper insights and behavioral trends. Add-on services include click-n-collect, reservations for in-store pickup, and local delivery.
ShareRails additionally offers Dress.li, which is a recommendation and reward platform that connects shoppers to stylists, bloggers and other fashion influencers who provide them with expert shopping advice and uniquely styled looks and, simultaneously, connects the consumers to fashion retailers. Through Dress.li, the challenge of creating a seamless social shopping experience has finally been mastered! This platform facilitates live shopping communications, curation and content creation and lets users join a global network of trendsetters. Through this network, users can inspire and be inspired, accessing and sharing product recommendations and unique looks and receiving rewards each time another user makes a purchase from their recommendations. This platform not only provides an enjoyable and exciting network for shoppers and fashionistas, but it simultaneously supplies retailers with a lucrative outlet for acquiring new customers through a built-in global sales force of fashion influencers. As these Dress.li stylists create and share looks, they also deliver pre-qualified sales leads and conversions and are rewarded for doing so.
Joined together, Grey Cloak Tech’s industry-leading click-fraud detection solutions and the exciting retail-boosting products delivered through ShareRails offer a broad package of services to both protect businesses in the digital world and help them utilize digital channels to bolster their sales and enhance customer engagement.
Grey Cloak Tech continues to serve as an industry leader in developing the most effective and comprehensive weapons to fight online security threats. The company is keenly focused on protecting its clients’ interests through the identification of fraud patterns at the very earliest stages. When businesses partner with Grey Cloak Tech, they can look forward to benefiting from industry-leading technology, a top-tier client services team, and an augmented bottom line.
For more information, visit the company’s website at www.GreyCloakTech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, April 10, 2017
CD International Enterprises, Inc. (CDII) Announces Engagement of QualityStocks Corporate Communications Suite
CD International Enterprises, Inc. (OTC: CDII), a U.S.-based company that sources industrial commodities and provides business and management corporate consulting services, today announced that it has engaged the Corporate Communications Services of QualityStocks.
“As a growing international brand, we want to maintain communication with our shareholders while increasing our online visibility and attracting new investors,” Dr. James Wang, chairman and CEO of CD International, stated in a news release. “We are excited to work with QualityStocks to achieve these communication goals and look forward to utilizing their expertise in this area.”
Under the agreement, QualityStocks will leverage its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to relay CD International’s corporate message and progress to the investment community.
“CD International is rapidly expanding its reach in China and the Americas, and most recently announced its plans to distribute cannabidiol (CBD) extract in the United States,” noted the QualityStocks Team. “Our goal is to provide the investment community with an accurate picture of how the company is growing its existing business, while working to capture its share of this new market.”
For more than 11 years, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value.
For more information, visit the company’s website at www.CDII.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“As a growing international brand, we want to maintain communication with our shareholders while increasing our online visibility and attracting new investors,” Dr. James Wang, chairman and CEO of CD International, stated in a news release. “We are excited to work with QualityStocks to achieve these communication goals and look forward to utilizing their expertise in this area.”
Under the agreement, QualityStocks will leverage its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to relay CD International’s corporate message and progress to the investment community.
“CD International is rapidly expanding its reach in China and the Americas, and most recently announced its plans to distribute cannabidiol (CBD) extract in the United States,” noted the QualityStocks Team. “Our goal is to provide the investment community with an accurate picture of how the company is growing its existing business, while working to capture its share of this new market.”
For more than 11 years, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value.
For more information, visit the company’s website at www.CDII.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
InMed Pharmaceuticals, Inc. (IMLFF) Offers More than Just a Non-THC Cannabinoid Drug Pipeline
Now that 28 states have passed comprehensive medical marijuana laws, conditions have never looked better for expanding research and development (R&D) into the therapeutic benefits of cannabinoids, which is exactly what InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is doing. Its efforts have already borne results: the company has two novel drug candidates in its pipeline. But there’s more to InMed than meets the eye; the Vancouver, Canada-based company has developed a proprietary process to manufacture cannabinoids based on biosynthesis. In addition, it has constructed an algorithm to identify the cannabinoids most likely to have beneficial therapeutic effect. With this triad of core assets, InMed looks poised to join the ranks of Big Pharma.
Of the 480 or so substances found in the cannabis sativa plant, about 60 are unique to the plant and are called cannabinoids. Perhaps the best known of these is delta-9-tetrahydrocannabinol (THC), which is responsible for the ‘high’ derived from marijuana, but cannabinol (CBN) and cannabinodiol (CBDL) will also get you stoned. Most other cannabinoids are not psychoactive and cannabidiol (CBD), the one which occurs the most in the plant (about 40 percent of cannabis resin), actually mitigates the psychoactive effects of THC.
CBD is also known to dispel anxiety, which, according to the Anxiety and Depression Association of America (http://dtn.fm/LUjx9), is the most common mental illness in the U.S., afflicting 40 million Americans. Cannabinoid R&D has the potential not only to ease their suffering but the burden of those who suffer from a variety of other ailments.
At InMed, R&D has led to the development of a proprietary process to manufacture cannabinoids. Traditionally, cannabinoid compounds have been isolated by processing and purifying cannabis resin from actual plants. Alternatively, synthetic cannabinoids are created in the lab in a costly, time-consuming process that, in the end, may not produce a substance quite like nature’s. The InMed approach is to apply cannabinoid DNA to E-coli bacteria. The E-coli DNA is then removed leaving just the cannabinoid DNA, which can then replicate, in a process known as biosynthesis.
Although novel as a means of developing cannabinoids, biosynthesis is widely employed in the pharmaceutical industry. For example, the insulin used by millions of diabetics worldwide on a daily basis is manufactured through biosynthesis.
InMed has also created a bioinformatics program that assists in the identification of novel cannabinoids to treat diseases based on the current non-cannabinoid drugs being used. The program uses comprehensive algorithms to integrate data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products, and an extensive database on over 90 individual cannabinoid drugs found in cannabis.
Using its own proprietary analytics program and manufacturing methodology, InMed has advanced two drug candidates along its pipeline. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder, called epidermolysis bullosa (EB), that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Also in pre-clinical trials is INM-085 for the treatment of glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma. It is targeting a large market. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and that the disease has blinded more than 120,000.
InMed continues to expand its cannabinoid R&D. This has already produced huge success for GW Pharmaceuticals (market cap: $3 billion) after its Sativex, derived from cannabis, was approved for the treatment of multiple sclerosis (MS).
For more information, visit the company’s website at www.InMedPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Of the 480 or so substances found in the cannabis sativa plant, about 60 are unique to the plant and are called cannabinoids. Perhaps the best known of these is delta-9-tetrahydrocannabinol (THC), which is responsible for the ‘high’ derived from marijuana, but cannabinol (CBN) and cannabinodiol (CBDL) will also get you stoned. Most other cannabinoids are not psychoactive and cannabidiol (CBD), the one which occurs the most in the plant (about 40 percent of cannabis resin), actually mitigates the psychoactive effects of THC.
CBD is also known to dispel anxiety, which, according to the Anxiety and Depression Association of America (http://dtn.fm/LUjx9), is the most common mental illness in the U.S., afflicting 40 million Americans. Cannabinoid R&D has the potential not only to ease their suffering but the burden of those who suffer from a variety of other ailments.
At InMed, R&D has led to the development of a proprietary process to manufacture cannabinoids. Traditionally, cannabinoid compounds have been isolated by processing and purifying cannabis resin from actual plants. Alternatively, synthetic cannabinoids are created in the lab in a costly, time-consuming process that, in the end, may not produce a substance quite like nature’s. The InMed approach is to apply cannabinoid DNA to E-coli bacteria. The E-coli DNA is then removed leaving just the cannabinoid DNA, which can then replicate, in a process known as biosynthesis.
Although novel as a means of developing cannabinoids, biosynthesis is widely employed in the pharmaceutical industry. For example, the insulin used by millions of diabetics worldwide on a daily basis is manufactured through biosynthesis.
InMed has also created a bioinformatics program that assists in the identification of novel cannabinoids to treat diseases based on the current non-cannabinoid drugs being used. The program uses comprehensive algorithms to integrate data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products, and an extensive database on over 90 individual cannabinoid drugs found in cannabis.
Using its own proprietary analytics program and manufacturing methodology, InMed has advanced two drug candidates along its pipeline. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder, called epidermolysis bullosa (EB), that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Also in pre-clinical trials is INM-085 for the treatment of glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma. It is targeting a large market. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and that the disease has blinded more than 120,000.
InMed continues to expand its cannabinoid R&D. This has already produced huge success for GW Pharmaceuticals (market cap: $3 billion) after its Sativex, derived from cannabis, was approved for the treatment of multiple sclerosis (MS).
For more information, visit the company’s website at www.InMedPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
